Oncgnostics Cervical Cancer Assay Receives Extended CE-IVD Mark

Feb 26, 2019

|

NEW YORK (GenomeWeb) – Oncgnostics announced recently that it has received an extended CE-IVD mark for the GynTect cervical cancer assay. As a result, researchers can run the assay on Roche Diagnostics' Cobas z 480 quantitative PCR-based analyzer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Oncgnostics Cervical Cancer Assay Receives Extended CE-IVD Mark

To read the full story....

Breaking News

AMP Cautions Against Using Cycle Threshold Values for PCR SARS-CoV-2 Tests in Clinical Practice

Prevencio, Atlas Genomics to Commercialize Cardiac Blood Tests

DiaSorin, Qiagen Obtain CE Mark for Lyme Disease Early Detection Test

Sherlock Bio Foundation Licenses CRISPR Tech to Cooper International, United PPE for COVID-19 Tests

FDA Grants EUA to Enzo Biochem Sample Collection Kit for COVID-19 Testing

Qiagen Nabs CE Mark for High-Throughput SARS-CoV-2 Test Kit

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

What's Popular?

Biocartis Files FDA Submission for Microsatellite Instability Test in Colorectal Cancer

European Union to Review Illumina's Planned Grail Acquisition Under New Guidance

PixCell Medical, Axonlab Ink European Distribution Deal for Point-of-Care Hematology Analyzer

Prostate Cancer Study Shows Oncotype DX GPS Test Accurately Measures Long-Term Outcomes

Biodesix's Proteomic Method for Predicting Immunotherapy Response Advancing Toward Market

Sponsorships